BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 15381643)

  • 1. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
    Hartmann F; Packer M; Coats AJ; Fowler MB; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Anker SD; Amann-Zalan I; Hoersch S; Katus HA
    Circulation; 2004 Sep; 110(13):1780-6. PubMed ID: 15381643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy.
    Hartmann F; Packer M; Coats AJ; Fowler MB; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Trawinski J; Amann-Zalan I; Hoersch S; Katus HA
    Eur J Heart Fail; 2004 Mar; 6(3):343-50. PubMed ID: 14987586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure.
    Schou M; Gustafsson F; Corell P; Kistorp CN; Kjaer A; Hildebrandt PR
    Am Heart J; 2007 Jul; 154(1):123-9. PubMed ID: 17584564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.
    Bettencourt P; Azevedo A; Pimenta J; Friões F; Ferreira S; Ferreira A
    Circulation; 2004 Oct; 110(15):2168-74. PubMed ID: 15451800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
    Olsson LG; Swedberg K; Cleland JG; Spark PA; Komajda M; Metra M; Torp-Pedersen C; Remme WJ; Scherhag A; Poole-Wilson P;
    Eur J Heart Fail; 2007 Aug; 9(8):795-801. PubMed ID: 17693380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative prognostic value of plasma and urinary N-terminal pro-B-type natriuretic peptide in patients with acute destabilized heart failure].
    Manzano-Fernández S; Januzzi JL; Boronat García M; Bonaque-González JC; Muñoz-Esparza C; Albaladejo-Otón MD; Pastor-Pérez FJ; Pastor P; Valdés M; Pascual-Figal DA
    Rev Esp Cardiol; 2011 May; 64(5):365-72. PubMed ID: 21397374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
    Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction.
    Campbell DJ; Mitchelhill KI; Schlicht SM; Booth RJ
    J Card Fail; 2000 Jun; 6(2):130-9. PubMed ID: 10908087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
    de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
    Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure.
    Rothenburger M; Wichter T; Schmid C; Stypmann J; Tjan TD; Berendes E; Etz C; Pioux A; Löher A; Wenzelburger F; Drees G; Hoffmeier A; Breithardt G; Scheld HH
    J Heart Lung Transplant; 2004 Oct; 23(10):1189-97. PubMed ID: 15477114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
    Gundogdu F; Bozkurt E; Kiziltunc A; Sevimli S; Arslan S; Gurlertop Y; Senocak H; Karakelleoglu S
    Echocardiography; 2007 Feb; 24(2):113-7. PubMed ID: 17313541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study.
    Mohammed AA; van Kimmenade RR; Richards M; Bayes-Genis A; Pinto Y; Moore SA; Januzzi JL
    Circ Heart Fail; 2010 May; 3(3):354-61. PubMed ID: 20332419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic use of right heart catheterization data in patients with advanced heart failure: how relevant are invasive procedures in the risk stratification of advanced heart failure in the era of neurohormones?
    Gardner RS; Henderson G; McDonagh TA
    J Heart Lung Transplant; 2005 Mar; 24(3):303-9. PubMed ID: 15737757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.
    Kragelund C; Grønning B; Køber L; Hildebrandt P; Steffensen R
    N Engl J Med; 2005 Feb; 352(7):666-75. PubMed ID: 15716560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure.
    Michtalik HJ; Yeh HC; Campbell CY; Haq N; Park H; Clarke W; Brotman DJ
    Am J Cardiol; 2011 Apr; 107(8):1191-5. PubMed ID: 21296322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes.
    Galvani M; Ottani F; Oltrona L; Ardissino D; Gensini GF; Maggioni AP; Mannucci PM; Mininni N; Prando MD; Tubaro M; Vernocchi A; Vecchio C;
    Circulation; 2004 Jul; 110(2):128-34. PubMed ID: 15197143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.